DexCom is a major player in the continuous glucose monitoring space, with steadily growing revenues and a breakout year in 2020. DXCM's market cap valuation has reached $40 billion, leading to high ...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

SAN DIEGO (AP) _ DexCom Inc. (DXCM) on Wednesday reported a loss of $2 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 2 cents. Losses, adjusted ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Dexcom, Inc. (NASDAQ:DXCM) stands against the other ...

DexCom, Inc. (DXCM) reported a net loss of 25 cents per share in the fourth quarter of 2009, a couple cents narrower than the Zacks Consensus Estimate for a net loss of 27 cents and significantly ...

(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.

Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor’s Business Daily ...